Summit TherapeuticsSMMT
SMMT
About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Employees: 105
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
171% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 24
95% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 38
20% more funds holding
Funds holding: 164 [Q3] → 197 (+33) [Q4]
0.83% more ownership
Funds ownership: 11.68% [Q3] → 12.51% (+0.83%) [Q4]
11% less capital invested
Capital invested by funds: $1.85B [Q3] → $1.65B (-$204M) [Q4]
33% less call options, than puts
Call options by funds: $36.2M | Put options by funds: $53.7M
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
36%
upside
Avg. target
$35
58%
upside
High target
$44
99%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 32% 1-year accuracy 57 / 176 met price target | 99%upside $44 | Buy Reiterated | 21 Jan 2025 |
Truist Securities Asthika Goonewardene 26% 1-year accuracy 7 / 27 met price target | 58%upside $35 | Buy Initiated | 8 Jan 2025 |
Wells Fargo Mohit Bansal 44% 1-year accuracy 11 / 25 met price target | 36%upside $30 | Overweight Initiated | 11 Dec 2024 |
Jefferies Brent Thill 69% 1-year accuracy 38 / 55 met price target | 40%upside $31 | Buy Initiated | 6 Dec 2024 |
Financial journalist opinion
Based on 7 articles about SMMT published over the past 30 days
Neutral
Business Wire
3 days ago
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2024 financial results and provide an operational update for the Company on Monday, February 24, 2025, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our.
Positive
The Motley Fool
5 days ago
3 Stocks That Could Trounce the Market in 2025
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
Neutral
Business Wire
1 week ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 116,725 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committ.
Positive
The Motley Fool
1 week ago
Is Summit Therapeutics a Millionaire Maker?
Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (SMMT -2.71%). The drugmaker's shares are up by nearly 540%, thanks to excellent clinical progress for its leading pipeline candidate, ivonescimab, a cancer treatment in development.
Positive
The Motley Fool
1 week ago
2 Stocks That Could Soar Again in 2025
Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (VKTX 3.50%) and Summit Therapeutics (SMMT -2.71%).
Neutral
The Motley Fool
3 weeks ago
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?
It can be exciting to buy a stock that has been red hot and to jump on the bandwagon -- but doing so can come with significant risks. At some point, there's a danger that the stock's rally could dissipate, and at that point, a sell-off may ensue.
Positive
The Motley Fool
4 weeks ago
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how analysts view a given stock.
Positive
The Motley Fool
1 month ago
Why Summit Therapeutics Stock Is Jumping Today
Shares of Summit Therapeutics (SMMT 15.40%) had jumped 14.3% at 11:31 a.m. ET on Tuesday.
Positive
Seeking Alpha
1 month ago
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)
Summit Therapeutics' stock rose 888% since September 2023, driven by positive Phase 3 data for ivonescimab showing superior PFS vs Keytruda in NSCLC. Phase 3 HARMONi-2 trial showed 11.14 vs 5.82 months PFS benefit over Keytruda, with OS data expected in first half of 2025. Company has strong cash position ($486.9M) but faces increased burn rate with multiple Phase 3 trials ongoing.
Neutral
Business Wire
1 month ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 145,550 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committ.
Charts implemented using Lightweight Charts™